Emerging Markets Earnings Roundup: Roche, Johnson & Johnson (Part 1)
This article was originally published in PharmAsia News
First quarter earnings by early birds Johnson & Johnson and Roche showed familiar currency headwinds in emerging markets and Japan.
You may also be interested in...
Launched in the U.S. in 2013, Olysio brought in $354 million in worldwide sales during the first quarter, including $291 million in the U.S. Now, J&J will undertake a pair of Phase III trials that could back an sNDA to add co-administration with Sovaldi to the drug’s labeling.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.